Article Text

PDF

Correspondence
Could abatacept directly target expanded plasmablasts in IgG4-related disease?
  1. Guillermo Carvajal Alegria1,2,
  2. Pierre Pochard1,
  3. Jacques-Olivier Pers1,
  4. Divi Cornec1,2
  1. 1INSERM ESPRI, ERI29/EA2216, European University of Brittany, Brest, France
  2. 2Service de Rhumatologie, CHRU Brest, Brest, France
  1. Correspondence to Dr Divi Cornec, Service de Rhumatologie, CHRU Brest, Hôpital de la Cavale Blanche, BP 824, Brest cedex F 29609, France; divi.cornec{at}chu-brest.fr

Statistics from Altmetric.com

Yamamoto et al1 recently reported the case of a patient with long-standing and relapsing IgG4-related disease (IgG4-RD), who developed secondary resistance to rituximab treatment but subsequently improved under abatacept infusions. This interesting observation drives important questions, regarding both IgG4-RD pathophysiology and abatacept mechanisms of action.

IgG4-RD is a systemic disease of unknown cause, affecting primarily middle-aged men, characterised by swelling of one or several organs (mainly pancreas, salivary and lachrymal glands, lymphadenopathy, retroperitoneal organs) with infiltration of IgG4-positive plasma cells and fibrosis of involved organs, and high serum IgG4 levels in half of the patients.2 ,3 Several diagnostic or classification systems have been proposed.4 ,5

Its pathophysiology is still ill-defined.6 IgG4-secreting plasmablasts are central players in the disease: they are the main infiltrating cells in affected organs, they are expanded in the circulation, are …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles